ANI Pharmaceuticals (NASDAQ:ANIP) CFO Sells $264,960.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen Carey sold 3,312 shares of the stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $80.00, for a total transaction of $264,960.00. Following the transaction, the chief financial officer owned 180,393 shares in the company, valued at approximately $14,431,440. The trade was a 1.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Down 0.2%

Shares of ANI Pharmaceuticals stock opened at $81.65 on Friday. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. ANI Pharmaceuticals, Inc. has a 1 year low of $61.17 and a 1 year high of $99.50. The firm’s 50-day moving average is $79.60 and its two-hundred day moving average is $79.41. The stock has a market cap of $1.86 billion, a price-to-earnings ratio of 20.67 and a beta of 0.44.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The company had revenue of $237.46 million for the quarter, compared to analysts’ expectations of $207.63 million. During the same period in the prior year, the business earned $1.70 EPS. The firm’s quarterly revenue was up 20.5% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, research analysts expect that ANI Pharmaceuticals, Inc. will post 8.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ANIP has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, June 1st. Five investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $107.33.

Institutional Trading of ANI Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of ANI Pharmaceuticals by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock valued at $103,022,000 after buying an additional 27,598 shares in the last quarter. State Street Corp raised its position in shares of ANI Pharmaceuticals by 2.2% in the 4th quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock valued at $57,405,000 after purchasing an additional 15,496 shares during the last quarter. UBS Group AG raised its position in shares of ANI Pharmaceuticals by 45.8% in the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after purchasing an additional 185,172 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in shares of ANI Pharmaceuticals by 19.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company’s stock valued at $43,399,000 after purchasing an additional 91,153 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of ANI Pharmaceuticals by 8.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company’s stock valued at $40,843,000 after purchasing an additional 43,523 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.